SAFETY AND IMMUNOGENICITY OF A NEW INACTIVATED HEPATITIS-A VACCINE INCONCURRENT ADMINISTRATION WITH A TYPHOID-FEVER VACCINE OR A TYPHOID-FEVER PLUS YELLOW-FEVER VACCINE

Citation
R. Dumas et al., SAFETY AND IMMUNOGENICITY OF A NEW INACTIVATED HEPATITIS-A VACCINE INCONCURRENT ADMINISTRATION WITH A TYPHOID-FEVER VACCINE OR A TYPHOID-FEVER PLUS YELLOW-FEVER VACCINE, Advances in therapy, 14(4), 1997, pp. 160-167
Citations number
13
Categorie Soggetti
Medicine, Research & Experimental","Pharmacology & Pharmacy
Journal title
ISSN journal
0741238X
Volume
14
Issue
4
Year of publication
1997
Pages
160 - 167
Database
ISI
SICI code
0741-238X(1997)14:4<160:SAIOAN>2.0.ZU;2-Q
Abstract
Two clinical studies were conducted to evaluate the safety and immunog enicity of concomitant administration of a new inactivated hepatitis A (HA) vaccine and either a typhoid fever (Vi) vaccine or a combination of Vi and yellow fever (YF) vaccines. In study 1, 62 healthy adults r eceived HA + Vi into the deltoid muscle on contralateral sides. In stu dy 2, 59 healthy adults received HA and a combined Vi/YF vaccine into the contralateral deltoid muscles. Reactogenicity was evaluated for 14 days following vaccination. Blood samples (for antibody titration) we re obtained prior to vaccination on days 0 and 28 in study 1 and prior to vaccination on day 0 and on days 14 and 28 in study 2. The overall rate of local reactions was 19% at the HA injection site and 75% at t he Vi injection site in study 1; the rate of systemic reactions was 41 %. In study 2, local reactions occurred at 27% and 78% of the HA and V i/YF injection sites; the rate of systemic reactions was 42%. All reac tions were transient. Twenty-eight days after vaccination, the serocon version rate was 100% for HA antibodies and 90% for the Vi vaccine in study 1. Rates of seroconversion in study 2 were 100% for the HA vacci ne, 92% for the Vi vaccine, and 100% for the YF vaccine. Although this study was not comparative, both tested combinations were safe and imm unogenic, and their routine use for persons at risk, such as travelers , can be recommended.